newsfilter
← Latest News
GlobeNewswire·

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

ANVS
  • Annovis Bio, Inc. (NYSE: ANVS) announced the issuance of U.S. Patent No. 12,582,632 B2 on April 02, 2026.
  • The patent covers the prevention & treatment of neurological injuries resulting from brain infections using buntanetap or related compounds.
  • Scientific research suggests infectious agents such as herpes simplex virus, HIV, COVID, Lyme disease bacteria, & gum disease bacteria may trigger Alzheimer's pathology.
  • The prevailing hypothesis states brain infections cause overproduction of amyloid-beta (Aβ) & tau proteins, which form plaques & tangles as a defense mechanism.
  • Chronic overexpression of these proteins over time may lead to a toxic cascade & eventual Alzheimer's disease.
  • Buntanetap's mechanism of action reduces the overproduction of neurotoxic aggregating proteins at the translational level.
  • The new patent claims cover preventive use in healthy individuals at risk of exposure as well as reversal of damage in affected individuals.
  • Current patent protection extends through the year 2044.
  • CEO Maria Maccecchini stated the patent underscores the company's commitment to addressing neurodegeneration from microbial & viral infections.
  • Annovis is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania.
  • Buntanetap is an investigational once-daily oral therapy that inhibits translation of neurotoxic proteins including APP, amyloid beta, tau, alpha-synuclein, & TDP-43.